| 查看: 685 | 回复: 1 | |||
[交流]
怎么翻译啊求助，JBT-101是什么求告知
|
|
abstract Ajulemic acid, a side-chain analog of D8 -THC-11-oic acid, was designed as a potent therapeutic agent free of the psychotropic adverse effects typical of most cannabinoids. Subsequent studies of ajulemic acid have yielded widely divergent findings on the occurrence of these adverse effects. To help resolve these discrepancies, we have prepared highly purified ajulemic acid using a different synthetic method than previously reported in the literature and compared its cannabinoid receptor binding constants with those obtained using several other preparations from different sources. Whereas CB2 binding did not vary greatly among all of the samples, the CB1 binding showed a wide range of affinities. The highly purified product (JBT-101) reported here had the weakest affinity for CB1 while the original preparation (HU-239) showed the strongest affinity for CB1. The CB1/CB2 ratio of affinities was 12.3 for JBT-101 whereas that for HU-239 was 0.19, a 65-fold difference. Functional responses such as catalepsy and hypothermia using JBT-101 versus HU-239 displayed reduced CB1 activity in keeping with the receptor binding data. Thus, earlier conclusions on the limited therapeutic index for ajulemic acid need to be reconsidered in the light of the data now obtained using JBT-101. 发自小木虫Android客户端 |
回复此楼» 猜你喜欢
283分材料与化工求调剂
已经有12人回复
-
349求调剂
已经有7人回复
-
296材料专硕求调剂
已经有11人回复
-
一志愿上海海洋大学083200食品学硕，求调剂，接受其他专业
已经有7人回复
-
材料340分调剂
已经有8人回复
-
316求调剂
已经有13人回复
-
321求调剂
已经有11人回复
-
315求调剂
已经有6人回复
-
330分求调剂
已经有13人回复
-
化工调剂303分，过四级
已经有9人回复
|
abstract Ajulemic acid, a side-chain analog of D8 -THC-11-oic acid, was designed as a potent therapeutic agent free of the psychotropic adverse effects typical of most cannabinoids. Subsequent studies of ajulemic acid have yielded widely divergent findings on the occurrence of these adverse effects. To help resolve these discrepancies, we have prepared highly purified ajulemic acid using a different synthetic method than previously reported in the literature and compared its cannabinoid receptor binding constants with those obtained using several other preparations from different sources. Whereas CB2 binding did not vary greatly among all of the samples, the CB1 binding showed a wide range of affinities. The highly purified product (JBT-101) reported here had the weakest affinity for CB1 while the original preparation (HU-239) showed the strongest affinity for CB1. The CB1/CB2 ratio of affinities was 12.3 for JBT-101 whereas that for HU-239 was 0.19, a 65-fold difference. Functional responses such as catalepsy and hypothermia using JBT-101 versus HU-239 displayed reduced CB1 activity in keeping with the receptor binding data. Thus, earlier conclusions on the limited therapeutic index for ajulemic acid need to be reconsidered in the light of the data now obtained using JBT-101. 发自小木虫Android客户端 |
2楼2017-02-07 10:27:37
